Cytomegalovirus Monitoring After Unrelated Hematopoietic Stem Cell Transplantation in North Macedonia – First Results (EFI 2025) - May 24, 2025 - Abstract #P49; Pres time: May 15, 2025; 05:30 PM - 07:00 PM; Location: Poster Area; "They were treated with valganciclovir 2 × 450 mg until clearance of the virus was achieved. In our country, patients don't receive pre-emptive therapy with letermovir for CMV management. That is the reason why it is important to have strategy for CMV DNAemia monitoring at least once a week in the first 100 days after HSCT."
Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Transplantation • CD33 • CD34
|
|
Meri Kirijas 1; Kristina Stamatovska 1; Sanja Kajevikj 1; Olivija Efinska Mladenovska 1; Gorjan Milanovski 1; Dejan Trajkov 1; Teodora Brnjarchevska Blazevska 1; Tamara Savevska 1; Sonja Genadieva Stavrikj 2; Aleksandra Pivkova Veljanovska 2; Lazar Chadievski 2; Aleksandar Petlichkovski 1
|